EBVP-II (EPIRUBICINE, BLEOMYCINE, VINBLASTINE, PREDNISONE) CHEMOTHERAPY BEFORE RADIOTHERAPY IN LOCALIZED HODGKINS-DISEASE - PHASE-II TRIAL

  • 1 January 1988
    • journal article
    • research article
    • Vol. 75  (8) , 789-794
Abstract
A new regimen of chemotherapy was used to reduce toxicity of EBVP I [9]: the number of injections and the doses of bleomycin and vinblastin were reduced by half, the duration of treatment by third. Fifty patients with Hodgkin''s disease stage I to IIIA, previously untreated, received three courses of this regimen before radiotherapy. Gastro-intestinal toxicity was similar and alopecia was more marked than with EBVP I. Immediate efficacy is similar, with 90% of complete remission and only one failure. This regimen is shorter and more intensive than EBVP I. It deserves larger comparison with previously used chemotherapy in a more extensive controlled trial.